Filing summary: Graphite Bio, Inc. 10-Q, quarter ended March 31, 2023
Entity mismatch: The request identifies LENZ Therapeutics, Inc., but the supplied filing is for Graphite Bio, Inc. (Nasdaq: GRPH). This summary reflects the filing provided, not LENZ Therapeutics.
Business context and reporting period
Graphite Bio is a clinical-stage gene-editing company. The unaudited quarter ended March 31, 2023 is compared with the quarter ended March 31, 2022. The company reported no product revenue and has no products approved for sale.
In January 2023, Graphite paused its Phase 1/2 CEDAR trial of nula-cel for sickle cell disease after a serious adverse event in the first patient, which the company considered likely related to treatment. In February, it discontinued nula-cel development, began exploring strategic alternatives, and announced a restructuring that reduced its workforce by approximately 50%. It plans to continue research on its early-stage non-genotoxic conditioning program.
Financial performance and position
Amounts below are in millions of dollars unless otherwise noted.
| Metric | Q1 2023 | Q1 2022 or comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $16.2 | $18.2 |
| General and administrative expense | $7.6 | $7.7 |
| Restructuring expense | $2.6 | None |
| Total operating expenses | $26.5 | $26.0 |
| Net loss | $23.9 | $25.8 |
| Net loss per share | $0.43 | $0.48 |
| Net cash used in operating activities | $21.1 | $21.2 |
Interest income was $2.6 million, compared with $0.1 million a year earlier, substantially offsetting the operating loss. Comprehensive loss was $23.4 million, including a $0.6 million unrealized investment gain. Profit margins are not meaningful because the company had no revenue.
At March 31, 2023, cash and cash equivalents were $69.8 million and marketable securities were $194.3 million, totaling $264.1 million. Total assets were $310.0 million; total liabilities were $33.8 million; and stockholders’ equity was $276.2 million. The filing reports no borrowings or conventional debt balance. Operating lease liabilities totaled $4.5 million.
Operating cash use was broadly stable year over year. Investing activities provided $43.2 million, mainly from $71.7 million of investment maturities, partly offset by $28.1 million of investment purchases and $0.4 million of property and equipment purchases. Cash, cash equivalents and restricted cash increased by $22.1 million during the quarter.
Material changes and unusual items
- R&D expense declined $2.0 million year over year, principally due to lower clinical-trial and contract-manufacturing activity, partly offset by higher personnel and facility costs.
- Operating expenses rose $0.5 million despite lower R&D and G&A, primarily because of $2.6 million in restructuring charges.
- The restructuring plan was expected to incur approximately $3.4 million in employee termination benefits; $2.5 million was charged in the quarter. The company also approved $4.0 million in cash retention bonuses for certain continuing employees, accrued over service through March 1, 2024.
- Cash and cash equivalents increased from $47.7 million at year-end 2022, while marketable securities declined from $235.8 million to $194.3 million, reflecting investment maturities and portfolio reallocation.
- Property and equipment rose to $33.1 million, including construction in progress for the company’s planned facility.
Outlook, risks and contingencies
Management said cash, cash equivalents and marketable securities were expected to fund the then-current operating plan for at least 12 months from issuance of the financial statements. In MD&A, it estimated funding through the fourth quarter of 2024. These are management estimates, not guarantees; the company expects continuing losses and may need additional financing.
Key risks include the consequences of the nula-cel discontinuation and adverse event, uncertainty around strategic alternatives, the limited scope of ongoing research, dependence on third-party and single-source suppliers, clinical and regulatory uncertainty, and the possibility that further funding may be unavailable or dilutive. The company disclosed a planned 85,165-square-foot facility lease with $81.0 million of future minimum payments; the lease had not commenced as of March 31, 2023. A tenant-improvement allowance of up to $14.9 million was expected to be fully used.
The company reported no material legal proceedings, no material changes to the risk factors in its 2022 Form 10-K, and no subsequent events through May 11, 2023. Management stated disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the filing identity: the supplied 10-Q is Graphite Bio’s, although the request names LENZ Therapeutics.
- Check subsequent disclosures on the strategic alternatives process and the company’s post-quarter operating plans.
- Track cash burn and reconcile the runway estimates, including the stated funding horizon through Q4 2024.
- Assess the financial and contractual implications of the planned $81.0 million facility lease and remaining construction commitments.
- Review developments related to the CEDAR adverse event, the nula-cel discontinuation, restructuring costs and retention obligations.